BioDrugs

, Volume 27, Issue 3, pp 275–279

Dasatinib: A Guide to Its Use in Chronic Myeloid Leukemia in the EU

  • Gillian M. Keating
  • Katherine A. Lyseng-Williamson
  • Paul L. McCormack
  • Susan J. Keam
Adis Drug Clinical Q&A

Abstract

Oral dasatinib (Sprycel®) is effective in the treatment of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML) or imatinib-resistant or imatinib-intolerant chronic-phase, accelerated-phase, or blast-phase CML. In particular, dasatinib is associated with better and faster responses than imatinib in patients with newly diagnosed chronic-phase CML. The response to dasatinib appears to be maintained in the longer-term. Dasatinib has an acceptable tolerability profile; it is associated with myelosuppression, with fluid retention being the most common nonhematologic adverse event. Thus, dasatinib is a highly effective, once-daily therapy for the first-line treatment of patients with chronic-phase CML and for the second-line treatment of imatinib-resistant or imatinib-intolerant CML.

References

  1. 1.
    Baccarani M, Dreyling M. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl. 4):105–7.PubMedGoogle Scholar
  2. 2.
    National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN guidelines): chronic myelogenous leukemia version 2.2013. Fort Washington (PA): National Comprehensive Cancer Network, 2012.Google Scholar
  3. 3.
    McCormack PL, Keam SJ. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2011;71(13):1771–95.PubMedCrossRefGoogle Scholar
  4. 4.
    Condorelli F, Genazzani AA. Dasatinib: is it all in the dose? BioDrugs. 2010;24(3):157–63.PubMedCrossRefGoogle Scholar
  5. 5.
    Sprycel (dasatinib) film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2012.Google Scholar
  6. 6.
    Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Hochhaus A, Boque C, Bradley Garelik M, et al. Molecular response kinetics and BCR-ABL reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib vs imatinib: DASISION 3-year follow-up [poster no. 1537]. 17th Congress of the European Hematology Association, Amsterdam; 14–17 Jun 2012.Google Scholar
  9. 9.
    Mayer J, Warzocha K, Huguet F, et al. Efficacy and safety of dasatinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): European subpopulation analysis of the phase 3 DASISION trial [abstract no. 0190]. Haematologica. 2012;97(Suppl. 1):75.Google Scholar
  10. 10.
    Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chromic myeloid leukemia. Blood. 2012;120(19):3898–905.PubMedCrossRefGoogle Scholar
  11. 11.
    Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010;95(2):232–40.PubMedCrossRefGoogle Scholar
  12. 12.
    Rea D, Vellenga E, Junghanss C, et al. Six-year follow-up of patients with imatinib-resistant or imatinib-intolerant chronic-phase chronic myeloid leukemia (CP-CML) receiving dasatinib [poster no. 1430]. 17th Congress of the European Hematology Association, Amsterdam; 14–17 Jun 2012.Google Scholar
  13. 13.
    Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113(25):6322–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010;116(16):3852–61.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Gillian M. Keating
    • 1
  • Katherine A. Lyseng-Williamson
    • 1
  • Paul L. McCormack
    • 1
  • Susan J. Keam
    • 1
  1. 1.AdisNorth ShoreNew Zealand

Personalised recommendations